Aytu Biopharma (AYTU) Gains from Investment Securities (2018 - 2022)

Aytu Biopharma (AYTU) has reported Gains from Investment Securities for 5 consecutive years, with $75000.0 the latest figure, recorded in Q4 2022.

• On a quarterly basis, Gains from Investment Securities fell 72.92% year-over-year to $75000.0 in Q4 2022; TTM through Dec 2023 was -$632000.0, a 78.03% decrease from a year earlier, with the FY2023 full-year figure at -$1.0 million, down 373.93% from the prior year.
• Gains from Investment Securities was $75000.0 for Q4 2022 at Aytu Biopharma, down from $550000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $3.3 million in Q4 2020 and troughed at -$10.5 million in Q2 2020.
• A 5-year average of -$828613.9 and a median of $29500.0 in 2019 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities surged 21986.67% in 2020 and slumped 91.64% in 2021, its largest moves.
• Over 5 years, Gains from Investment Securities stood at $4633.0 in 2018, then surged by 223.76% to $15000.0 in 2019, then surged by 21986.67% to $3.3 million in 2020, then tumbled by 91.64% to $277000.0 in 2021, then slumped by 72.92% to $75000.0 in 2022.
• The last three Gains from Investment Securities figures came in at $75000.0 (Q4 2022), $550000.0 (Q2 2022), and -$1.3 million (Q1 2022), per Business Quant data.